PAXMAN publishes its interim report for the period 1 January to 31 March 2018
A strong first quarterThe Group’s sales amounted to 11.0 MSEK in the first quarter of the year, with a net loss totalling -1.7 MSEK. Earnings per share were -0.10 SEK for the period. Cash flow before financing activities was -6.8 MSEK. Total assets amounted to 43.7 MSEK at 31 March, and net liquid assets to -1.2 MSEK. Equity to assets ratio was 71.7 % at the end of the reporting period. The 10 MSEK credit line secured earlier this year is yet to be utilized. In the first quarter of the year, PAXMAN signed a license agreement for Mexico with Teva Pharmaceutical Industries, which means